Here’s what you should know.
1. Analysts view Valeant’s $2.1 billion sell-off of four of its assets in a largely positive manner after Valeant received eight times the annual combined revenue for its three skincare products. Valeant completed the sell-off in January 2017.
2. Valeant was also able to turnaround its Dendreon’s assets for $819.9 million after acquiring them for $445 million after Dendreon filed bankruptcy.
3. Valeant also saw the share of its portfolio held by short sellers drop from $33.7 million to $29.1 million. That drop could note the beginning of an attitude shift towards Valeant.
4. Motley Fool analysts believe, as a whole, Valeant is becoming a more attractive company because of CEO Joe Papa’s ability to sell off assets for attractive returns.
5. However, the analysts also argue if Valeant doesn’t reinvent its sales team and regain the trust of the public and physicians, then it’s lingering $30.4 billion in debt could continue to crush the company.
More articles on gastroenterology/endoscopy:
GI leader to know: Dr. Abraham Panossian of East Valley Gastroenterology & Hepatology Associates
FDA issues updated guidance on off-label communications: 6 key notes
Do fiber-based diets increase or decrease the risk of colorectal cancer? 5 study takeaways
